



Lund, December 11, 2023

## **PRESS RELEASE**

# **Hamlet BioPharma is inviting you to join a digital presentation at Invest Live, Tuesday December 12<sup>th</sup> at 12.00 CET**

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to invite you to join a presentation at Invest Live, on Tuesday December 12<sup>th</sup> at 12.00 CET.

Gain insights into the company's latest progress within its infectious disease and cancer therapy, which includes 'Fast Track' status for the company's cancer-drug Alpha1H.

We welcome share holders, investors and other interested parties to join the presentation and discussion.

The presentation will be held in English.

Use this link to view the presentation:

<https://youtu.be/eXGYz0-ot8>

### **For further information, please contact:**

Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49  
catharina.svanborg@hamletpharma.com

Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77  
martin.erixon@hamletpharma.com

[www.hamletbiopharma.com](http://www.hamletbiopharma.com)